LifeMine
Drug Discovery · Prescription Drugs
1open role
$263Mlatest round · Venture round · Aug 2026 · 3 mo ago
3backers · RA Capital Management, ARCH Venture Partners
500+team · employees, estimated range
Overview
LifeMine is a clinical-stage biopharmaceutical company pioneering a bold new approach, Top-Down Drug DiscoveryTM, which leverages evolutionary insights from fungi to unearth next-generation precision medicines.
Key facts
As of Nov 13, 2026, Alion lists 1 open role at LifeMine. LifeMine is headquartered in Cambridge, United States. It was founded in 2017. The latest round is Venture - Series Unknown of $263M, announced in 2026.
- Open roles
- 1Its careers board, read on Nov 13, 2026
- Headquarters
- Cambridge, United StatesAlion company profile, updated Nov 12, 2026
- Founded
- 2017Alion company profile, updated Nov 12, 2026
- Employees
- 500+Alion company profile, an estimated range
- Total raised
- $263MSum of 1 equity round Alion knows
- Latest round
- Venture - Series Unknown · $263M · Aug 6, 2026Press report
Funding and backers
Total raised
$263M
1 round on record
Latest round
$263M
Venture round · Aug 2026 · 3 mo ago
Team
501-1000
employees, estimated range
Hiring now
1
open roles
Backers
3
RA Capital Management, ARCH Venture Partners
The money's age
Fresh money
3 months since the last round · hiring slowed
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Aug 2026 | $263M | — | streetinsider.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation…
Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of…
OliX Pharmaceuticals is a South Korean biopharmaceutical company that develops new drugs for various diseases based on RNA interference…
Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of…
CAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor…
GH Research is a clinical-stage pharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Jobs
≈ $86k – $252k per year (Estimated) · In office · 12+ years exp · Bachelor's Degree · Watertown
Apply
Growth
Hiring Momentum
48/100
Stable
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~6 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Early Careers
100% ▼
Financials
Total raised
$263M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount |
|---|---|---|
| Venture - Series Unknown | 2026 | $263M |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
ARCH Venture PartnersVia a fund
RA Capital ManagementVia a fund
GVVia a fund
569 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants
The post LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants appeared first on LifeMine.
Read more
Report
Greg Verdine's LifeMine raises $263M for safer immunosuppressant
The post Greg Verdine's LifeMine raises $263M for safer immunosuppressant appeared first on LifeMine.
Read more
Report
A scientist-turned-biotech executive is notching some wins, and enjoying it
The post A scientist-turned-biotech executive is notching some wins, and enjoying it appeared first on LifeMine.
Read more
Report
Scientist-turned-biotech executive Greg Verdine is notching some wins, and enjoying it - The Boston Globe
Read more
Report
LifeMine Therapeutics Raises $263 Million To Advance LIFE-001 For Organ Transplantation
LifeMine Therapeutics has secured $263 million in financing to accelerate the clinical development of LIFE-001 and advance its broader pipeline of transplantation and immunology therapies. The financing includes an oversubscribed $188 million Series E rou
Read more
Report
LifeMine Raises $263 Million to Accelerate the Clinical Development of LIFE-001, a Structurally and Mechanistically Novel Calcineurin Activation Inhibitor Designed to Transform Organ Transplantation
The post LifeMine Raises $263 Million to Accelerate the Clinical Development of LIFE-001, a Structurally and Mechanistically Novel Calcineurin Activation Inhibitor Designed to Transform Organ Transplantation appeared first on LifeMine.
Read more
Report
LifeMine Raises $263 Million to Accelerate the Clinical Development of LIFE-001, a Structurally and Mechanistically Novel Calcineurin Activation Inhibitor Designed to Transform ...
Read more
Report
LifeMine Announces First Participant Dosed in First-in-human Phase 1 Clinical Trial of LIFE-001, Designed De Novo to Become a Field Dominating Immunosuppressive for Immune-mediated Disorders and Transplantation
The post LifeMine Announces First Participant Dosed in First-in-human Phase 1 Clinical Trial of LIFE-001, Designed De Novo to Become a Field Dominating Immunosuppressive for Immune-mediated Disorders and Transplantation appeared first on LifeMine.
Read more
Report
Genomic Discovery and Structure-Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors
The post Genomic Discovery and Structure-Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors appeared first on LifeMine.
Read more
Report
Greg Verdine: What is LifeMine's Mission?
The post Greg Verdine: What is LifeMine's Mission? appeared first on LifeMine.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
4
Hiring now
1
Countries
2
Busiest office
Watertown
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cambridge
United States
HQ
Watertown
United States
Regional office
Watertown, MA
1 open roles 1 posted in 90 days 500-1000 est. staff
hires for Early Careers
Basel
Switzerland
Regional office
Basel, CH
Gloucester
United States
Regional office
Gloucester, MA
How to cite this page
Alion, "LifeMine: key facts", as of Nov 13, 2026. https://alion.io/company/lifeminetx
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0